Page 154 - CW E-Magazine (15-10-2024)

Pharmaceuticals Hydrocarbons

COUNTER COLLABORATION
IPA reacts to reports of 50 medicines failing quality BPCL and Mumbai Port Authority to launch India’s

tests fi rst green fuel ecosystem

The Indian Pharmaceutical Alliance termed the medicines fl agged in the medicines on a global stage.” He added Bharat Petroleum Corporation Ltd.
(IPA) has reacted to a recent report by report as “counterfeits” not manufac- that a clear distinction between NSQ and (BPCL) has signed a memorandum of
the Central Drugs Standard Control tured by them, while asserting that their spurious drugs must be made. Stating understanding (MoU) with the Mumbai
Organisation (CDSCO) according to products conform to quality standards. the issue as of paramount importance Port Authority (MbPA) and the Mumbai
which over 50 drugs were found of “not for India’s global standing, Mr. Jain said Port Sustainability Foundation (MPSF) to
of standard quality (NSQ).” Clear distinction between NSQ and that IPA will continue to work with the create a green fuel ecosystem at Mumbai
spurious drugs must be made government to strengthen the overall Port.
The association said there is a need In a statement, IPA Secretary General, system and establish stringent measures
for a clear distinction between spu- Mr. Sudarshan Jain said, “Manufac- against spurious drugs. “The MoU is a pivotal step towards
rious and sub-standard drugs, adding that turing spurious drugs is a serious crimi- driving India’s transition to cleaner energy
linking counterfeit products with legit- nal offence. The outrageous linking of Mr. Jain noted that the pharma solutions. By focusing on green fuel
imate manufacturers has severe reputa- spurious products with legitimate manu- sector is of strategic importance to the innovations, this initiative aims to signi-
tional and fi nancial impact. Several drug facturers has severe reputational and nation, and plays a vital role in supplying fi cantly reduce greenhouse gas emis- both recyclable and non-recyclable solid Mr. Krishna Kumar, CMD, BPCL,
fi rms, including Torrent, Sun Pharma, fi nancial impact. Moreover, this tarnishes affordable quality-assured medicines to sions, contributing to the country’s cli- waste at Mumbai Port. This initiative said the MoU aligns with BPCL’s com-
Alkem Laboratories and Glenmark, India’s reputation as a reliable supplier of over 200 countries. mate change goals,” a BPCL statement fosters socially responsible practices, mitment to a sustainable future, as well
said. As part of this initiative, BPCL and contributing to a cleaner and more sus- as its goal of reaching net zero emissions
DRUG DISCOVERY MbPA will work together to establish tainable operational environment. for Scope 1 and Scope 2 by 2040.
Mr. Rahul Tandon, Business Head (I&C)
US FDA grants fast-track designation to Wockhardt’s electric vehicle (EV) charging stations “This collaboration exemplifi es the at BPCL, said that by leveraging LNG
at Mumbai Port. Additionally, the MoU
antibiotic includes plans to explore the conversion use of innovative technologies and solu- and green energy infrastructure, the
of diesel-powered vessels to cleaner fuel tions to drive research and development company strives to transform the future
alternatives, further enhancing the port’s in the energy sector. BPCL’s leadership of maritime operations. “This collabora-
Wockhardt’s antibiotic for urinary has successfully completed a Phase green infrastructure and minimising its in this space reinforces its role in shaping tion refl ects our commitment to driving
tract infections has been granted “fast I study conducted by the Division of carbon footprint. The agreement also India’s sustainable future, making Mumbai innovation in fuel solutions that not only
track designation” by the US FDA. Microbiology and Infectious Diseases addresses waste management, with BPCL Port a model of environmental respon- reduce carbon emissions but also create
(DMID) at the National Institute of and MPSF collaborating on systems for sibility for ports nationwide,” BPCL long-term value for the environment and
The drug, codenamed WCK 6777, Allergy and Infectious Diseases (NIAID), the segregation, storage, and handling of said in the statement. the industry,” he said.
has also completed Phase I study con- part of the National Institutes of Health
ducted by the National Institutes of (NIH) in US,” the company said in ECOLOGICAL IMPACT
Health, US. In an exchange fi ling on a statement. Earlier this month, the
October 7 Wockhardt said, “recognizing bacterial infections that drive anti- pharma company said one of its LNG’s 20-year greenhouse gas footprint 30% more
its potential to meet signifi cant unmet microbial resistance (AMR). “β-lactam investigational drugs – Zaynich – has
medical needs, the US FDA has recently enhancer based MDR-active antibiotic, successfully treated critically ill patients than coal’s: Study
granted Fast Track designation to WCK WCK 6777 (Ertapenem/Zidebactam) of drug-resistant meningitis.
6777 for the treatment of complicated Liquefi ed natural gas (LNG) leaves to form LNG, thereby reducing the University, US, said. “LNG is made from
urinary tract infections (cUTI), includ- Mylan settles patent suit with Novo behind a greenhouse gas footprint gas’s original volume by 600 times. shale gas (a type of natural gas), and to
ing pyelonephritis, and complicated about a third more than that of coal Being liquid, LNG can be shipped make it you must supercool it to liquid
intra-abdominal infections (cIAI).” Nordisk over generic Ozempic when looked at over a 20-year period, effi ciently and safely. form and then transport it to market in
according to a new study. Over a 100- large tankers. That takes energy. While
WCK 6777 is the only once-a-day Natco Pharma Ltd. has said its ment of generic Ozempic (Semaglutide) year period, LNG’s greenhouse gas Although LNG is considered a cleaner, natural gas and shale gas are all bad for
drug in the global antibiotic pipeline partner Mylan Pharmaceuticals Inc. has products, the company said in a regu- footprint was found to be the same as low-carbon alternative to coal, when the climate, LNG is worse,” Dr. Howarth,
designed for outpatient parenteral anti- reached a patent litigation settlement latory fi ling. Ozempic is a prescription or exceeding that of coal. processing and shipping are taken into author of the study published in the
microbial therapy (OPAT), it said. The with Novo Nordisk in the US over medication patented by Novo Nordisk. account, its greenhouse gas footprint journal Energy Science and Engineering,
company is advancing the development generic Ozempic, a drug used to lower Natural gas, an odourless gas pri- is about a third worse than that of coal, said. Shale gas is extracted from shale
of several new antibiotics aimed at blood sugar and weight loss. Natco and The terms of the settlement are marily made up of methane, is cooled Dr. Robert Howarth, a professor of ecology rock formations through a process called
combating diffi cult-to-treat drug-resistant Mylan have partnered for the develop- confi dential, it added. down to a liquid state at about -106°C and environmental biology at Cornell ‘fracking’. For the study, the researchers

154 Chemical Weekly October 15, 2024 Chemical Weekly October 15, 2024 155

Contents Index to Advertisers Index to Products Advertised